WHAT IS CLAIMED IS:

1. Use of apalutamide in the manufacture of a medicament for the treatment of nonmetastatic castration-resistant prostate cancer in a patient in need thereof; wherein the medicament is to be administered in combination with androgen deprivation therapy, and wherein the median metastasis free survival for a population of patients who are administered the medicament in combination with androgen deprivation therapy is 40.5 months.

2. The use of claim 1, wherein the non-metastatic castration-resistant prostate cancer is a high risk non-metastatic castration-resistant prostate cancer.

3. The use of claim 2, wherein the patient has said non-metastatic castration-resistant prostate cancer and has a prostate-specific antigen doubling time (PSADT) that is less than or equal to 10 months.

4. The use of any one of the preceding claims, wherein the patient having said non-metastatic castration-resistant prostate cancer has received at least one prior therapy for the treatment of cancer.

5. The use of claim 4, wherein the prior therapy for the treatment of cancer is bicalutamine or flutamide.

6. The use of any one of claims 1 to 3, wherein the patient having said non-metastatic castration-resistant prostate cancer is treatment naïve.

7. The use of any one of the preceding claims, wherein the patient having said non-metastatic castration-resistant prostate cancer is an adult.

8. The use of any one of the preceding claims, wherein if the patient experiences a greater than or equal to Grade 3 toxicity or an intolerable side effect, dosing of the medicament is to be held until symptoms of the greater than or equal to Grade 3 toxicity improve to less than or equal to Grade 1 or original grade; and daily oral administration of the medicament is to be resumed in an amount of about 240 mg, 180 mg, or 120 mg.

9. The use of any one of the preceding claims, wherein the treatment comprises

(a) a daily oral dose of the medicament to be administered in an amount of about 240 mg;
(b) if the patient experiences a greater than or equal to Grade 3 toxicity or an intolerable side effect, dosing of the medicament is to be held until symptoms of the greater than or equal to Grade 3 toxicity improve to less than or equal to Grade 1 or original grade; and daily oral administration of the medicament is to be resumed in an amount of about 240mg, 180 mg, or 120 mg.

10. The use of any one of the preceding claims, wherein the medicament comprising apalutamide is to be administered daily to the patient.

11. The use of any one of the preceding claims, wherein the medicament comprising apalutamide is to be administered orally on a continuous daily dosage schedule.

12. The use of any one of the preceding claims, wherein the medicament comprising apalutamide is to be administered orally at a dose of about 240 mg per day.

13. The use of any one of the preceding claims, wherein the medicament comprising apalutamide is to be administered orally as four tablets comprising about 60 mg of apalutamide per tablet, wherein the four tablets are to be administered once daily.

14. The use of any one of the preceding claims, wherein the medicament comprising apalutamide is to be administered orally at a dose of about 240 mg per day, wherein the apalutamide is present in four tablets comprising about 60 mg of apalutamide per tablet.

15. The use of any one of the preceding claims, wherein the apalutamide is present in four tablets comprising about 60 mg of apalutamide per tablet.

16. The use of any one of the preceding claims, wherein the medicament is present in a solid dosage form.

17. The use of claim 15, wherein the medicament is formulated as a tablet.

18. The use of any one of the preceding claims, wherein the increase in median metastasis free survival for the population of patients who are administered the medicament in combination with

androgen deprivation therapy is greater than 20 months, as compared to the median metastasis free survival for a population of patients who are administered androgen deprivation therapy in combination with a placebo.

19. The use of any one of the preceding claims, wherein the median metastasis free survival for the population of patients who are administered androgen deprivation therapy and placebo is 16.2 months.